97212 Ventures is a venture capital firm that focuses on investing in early-stage technology startups. The firm provides capital, mentorship, and strategic support to entrepreneurs aiming to drive innovation and growth in various sectors.

97212 is a seed fund exclusively focused on investing in top early stage Israeli startups committed to building category defining companies in NYC. Our check is just the beginning. We jump in, roll up our sleeves and provide hands-on tangible value from day one, so Israeli founders can truly cut time to market and build a global business from day one. 

Every company we invest in goes through a personalized process designed to hit 3 company moments - early traction, funding, and product-market-fit, while eliminating unnecessary detours. 

www.97212.vc

97212 Ventures

Congratulations to Permit.io, on their successful Series A funding round led by Scale Venture Partners, and on the launch of their groundbreaking product, Permit.io Approval Flows

This solution is set to revolutionize the way enterprises handle complex authorizations, including for AI bots and agents

We're looking forward to supporting the team, and seeing the growth of this company!

#aibusiness 
#fundinground 
#foundersjourney 
https://lnkd.in/esJF5ZCB

Big news!👏

Former Prime Minister Israeli Naftali Bennett, is joining the board of Remepy, a pioneer in the field of hybrid medications to enhance the drug effect, and one of the exciting portfolio companies at 97212 Ventures.
 
Remepy is at the forefront of developing hybrid drugs that enhance the effect of traditional medications. Their ground-breaking work has the potential to improve medical outcomes in a range of areas, including neurological diseases, cancer, autoimmune diseases, and degenerative eye diseases.
 
Congratulations to the entire Remepy team on this exciting new chapter. 

#healthcare 
#israelinnovation 
#futureofhealth 
 https://lnkd.in/gEBRNycA

VC:97212

97212 Ventures

Analysis Not Available